Allergy & Immunology prior authorization at Healthfirst
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Healthfirst allergy & immunology PA at a glance
Healthfirst reviews allergy & immunology PA submissions against its medical policy library, with rules drawn primarily from AAAAI (American Academy of Allergy, Asthma & Immunology) + GINA for asthma + HAEA for HAE. Healthfirst-specific context: Provider-sponsored not-for-profit; largest Medicaid MCO in NY State (~1.8M members). Owned by ~30 NY hospital systems. NY DFS oversight. NY State Fair Hearing is escalation path for Medicaid denials; commercial appeals go to DFS external appeal program.
Documentation packet — what to send
- Diagnosis with ICD-10 (severe asthma, CIU, AD, HAE)
- Biomarkers (eos, IgE, FeNO, C1-INH activity)
- Prior therapies tried
- Severity / attack-frequency documentation
Common denial patterns to pre-empt
Patterns observed in allergy & immunology across payers, and where Healthfirst's book of business overlaps:
- Asthma biologics: eosinophil / IgE / FeNO phenotyping not met
- Allergen immunotherapy: not tried before omalizumab in CIU
- Atopic dermatitis biologic: severity threshold not met
- Hereditary angioedema (HAE) prophylaxis: attack-frequency threshold not met
Appeal angles when Healthfirst denies
- GINA / AAAAI guideline citation
- Phenotype biomarker documentation (eos, IgE, FeNO)
- HAE: attack frequency documented over 3+ months pre-prophylaxis
Peer-to-peer prep
- Quote the AAAAI / GINA guideline
- For severe asthma biologic selection: match phenotype to drug (T2-high vs allergic vs eosinophilic)
- For HAE: bring attack-frequency log and C4 / C1-INH labs
- For CIU: document urticarial activity score (UAS7) trend
Drug-specific PA criteria at Healthfirst
Deep dives on each drug's PA criteria at Healthfirst:
Frequently asked questions
What documentation does Healthfirst need for allergy & immunology prior authorizations?
Healthfirst's PA packet for allergy & immunology typically includes: Diagnosis with ICD-10 (severe asthma, CIU, AD, HAE); Biomarkers (eos, IgE, FeNO, C1-INH activity); Prior therapies tried; Severity / attack-frequency documentation. AAAAI (American Academy of Allergy, Asthma & Immunology) + GINA for asthma + HAEA for HAE citations strengthen the submission.
What's the turnaround at Healthfirst?
Healthfirst standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 60 days.
Which allergy & immunology drugs does Healthfirst most often PA-restrict?
Top targets in allergy & immunology: dupilumab, omalizumab, mepolizumab, tezepelumab. Each follows the per-drug step therapy + documentation requirements published in Healthfirst's medical policy library.
How do I prep a peer-to-peer with Healthfirst in allergy & immunology?
Quote the AAAAI / GINA guideline For severe asthma biologic selection: match phenotype to drug (T2-high vs allergic vs eosinophilic) Have the policy URL and the patient's chart open before the call.
Generate a Allergy & Immunology PA packet
Open ApprovalHelp — generate a allergy & immunology PA packet tailored to Healthfirst's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com